Zanzalintinib

Zanzalintinib (also known as XL092) is an oral drug that is undergoing clinical studies. It could potentially be used to treat renal cell carcinoma (RCC). It is being developed by Exelixis.

STELLAR-303 is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in metastatic colorectal cancer.

STELLAR-304 (NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC).